{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:25:20Z","timestamp":1763447120346,"version":"3.45.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06174","JP22K06933"],"award-info":[{"award-number":["JP23K06174","JP22K06933"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jphs.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:44:41Z","timestamp":1758591881000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rho kinase 2 promotes epithelial-mesenchymal transition and proliferation in human prostate cancer PC-3\u00a0cells"],"prefix":"10.1016","volume":"159","author":[{"given":"Alamgir","family":"Hossain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-4471","authenticated-orcid":false,"given":"Aya","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Junayed","family":"Nayeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivasundaram","family":"Karnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.jphs.2025.09.007_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41585-018-0060-7","article-title":"Landmarks in prostate cancer","volume":"15","author":"Sathianathen","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.007_bib3","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.007_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.bbamcr.2009.01.009","article-title":"Insights into Ca2+ homeostasis of advanced prostate cancer cells","volume":"1793","author":"Flourakis","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jphs.2025.09.007_bib5","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29846","article-title":"Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions","volume":"5","author":"Julian","year":"2014","journal-title":"Small GTPases"},{"issue":"4","key":"10.1016\/j.jphs.2025.09.007_bib6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1124\/pr.115.010595","article-title":"Rho kinases in health and disease: from basic science to translational research","volume":"67","author":"Loirand","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jphs.2025.09.007_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fphar.2015.00276","article-title":"The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease","volume":"6","author":"Hartmann","year":"2015","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jphs.2025.09.007_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00005-015-0382-6","article-title":"Novel insights into the roles of Rho kinase in cancer","volume":"64","author":"Wei","year":"2016","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.jphs.2025.09.007_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-med-051914-022120","article-title":"Rho kinases in autoimmune diseases","volume":"67","author":"Pernis","year":"2016","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.007_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.115.306532","article-title":"RhoA\/Rho-kinase in the cardiovascular system","volume":"118","author":"Shimokawa","year":"2016","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jphs.2019.01.008","article-title":"Calcilytics inhibit the proliferation and migration of human prostate cancer PC-3 cells","volume":"139","author":"Yamamura","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2025.09.007_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.667474","article-title":"MAZ51 blocks the tumor growth of prostate cancer by inhibiting vascular endothelial growth factor receptor 3","volume":"12","author":"Yamamura","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.007_bib13","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1096\/fj.201802620R","article-title":"Platelet-derived growth factor up-regulates Ca2+-sensing receptors in idiopathic pulmonary arterial hypertension","volume":"33","author":"Yamamura","year":"2019","journal-title":"FASEB J"},{"key":"10.1016\/j.jphs.2025.09.007_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbrc.2020.10.106","article-title":"The Rho kinase 2 (ROCK2)-specific inhibitor KD025 ameliorates the development of pulmonary arterial hypertension","volume":"534","author":"Yamamura","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.jphs.2025.09.007_bib15","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.007_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41420-023-01552-5","article-title":"CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma","volume":"9","author":"Karnan","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jphs.2025.09.007_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120171","article-title":"Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-\u03b1","volume":"288","author":"Nayeem","year":"2022","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.007_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.jphs.2025.09.007_bib19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial-mesenchymal transitions","volume":"119","author":"Zeisberg","year":"2009","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.jphs.2025.09.007_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.007_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-5793(96)00811-3","article-title":"ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice","volume":"392","author":"Nakagawa","year":"1996","journal-title":"FEBS Lett"},{"issue":"23-24","key":"10.1016\/j.jphs.2025.09.007_bib22","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.drudis.2013.09.010","article-title":"Advances in the development of Rho-associated protein kinase (ROCK) inhibitors","volume":"18","author":"Pan","year":"2013","journal-title":"Drug Discov Today"},{"issue":"25","key":"10.1016\/j.jphs.2025.09.007_bib23","doi-asserted-by":"crossref","first-page":"21093","DOI":"10.1074\/jbc.M111.330381","article-title":"MicroRNA-148a promotes myogenic differentiation by targeting the ROCK1 gene","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jphs.2025.09.007_bib24","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1159\/000443117","article-title":"MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating Rho-associated protein kinase 1 (ROCK1)","volume":"38","author":"Zhou","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"10.1016\/j.jphs.2025.09.007_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110293","article-title":"MicroRNA-129-5p-mediated translational repression of microglial ROCK1 leads to enhanced phagocytosis","volume":"301","author":"Dey","year":"2025","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jphs.2025.09.007_bib26","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.12659\/MSM.912098","article-title":"Rho-associated protein kinase (ROCK) promotes proliferation and migration of PC-3 and DU145 prostate cancer cells by targeting LIM kinase 1 (LIMK1) and matrix metalloproteinase-2 (MMP-2)","volume":"25","author":"Gong","year":"2019","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0002-9440(10)65177-2","article-title":"N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells","volume":"155","author":"Tran","year":"1999","journal-title":"Am J Pathol"},{"issue":"17","key":"10.1016\/j.jphs.2025.09.007_bib28","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.yexcr.2011.07.024","article-title":"N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K\/Akt signaling in prostate cancer cells","volume":"317","author":"Nalla","year":"2011","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.007_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/cells8020143","article-title":"Epithelial-to-mesenchymal transition markers and CD44 isoforms are differently expressed in 2D and 3D cell cultures of prostate cancer cells","volume":"8","author":"Fontana","year":"2019","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.jphs.2025.09.007_bib30","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3390\/cancers13194985","article-title":"Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis","volume":"13","author":"Usman","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jphs.2025.09.007_bib31","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/cancers13112795","article-title":"Cell plasticity and prostate cancer: the role of epithelial-mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance","volume":"13","author":"Papanikolaou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.007_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acn3.19","article-title":"Selective ROCK2 inhibition in focal cerebral ischemia","volume":"1","author":"Lee","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.007_bib33","first-page":"244","article-title":"Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"10.1016\/j.jphs.2025.09.007_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139094","article-title":"LPA induces colon cancer cell proliferation through a cooperation between the ROCK and STAT-3 pathways","volume":"10","author":"Leve","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2025.09.007_bib35","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1038\/srep09437","article-title":"Annexin V-induced rat Leydig cell proliferation involves Ect2 via RhoA\/ROCK signaling pathway","volume":"5","author":"Jing","year":"2015","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.jphs.2025.09.007_bib36","doi-asserted-by":"crossref","first-page":"14397","DOI":"10.18632\/oncotarget.24208","article-title":"RhoA\/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jphs.2025.09.007_bib37","first-page":"2632","article-title":"Significant association of Rho\/ROCK pathway with invasion and metastasis of bladder cancer","volume":"9","author":"Kamai","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib38","first-page":"585","article-title":"The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer","volume":"33","author":"Lane","year":"2008","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.jphs.2025.09.007_bib39","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/hep.22836","article-title":"Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion","volume":"49","author":"Wong","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3892\/or.2017.5397","article-title":"Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy","volume":"37","author":"Pinca","year":"2017","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.jphs.2025.09.007_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s13046-019-1506-3","article-title":"ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity","volume":"38","author":"Zucchini","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","article-title":"Preclinical to clinical utility of ROCK inhibitors in cancer","volume":"9","author":"Barcelo","year":"2023","journal-title":"Trends Cancer"},{"issue":"7132","key":"10.1016\/j.jphs.2025.09.007_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jphs.2025.09.007_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1369\/0022155412470834","article-title":"Regulation of ROCK activity in cancer","volume":"61","author":"Morgan-Fisher","year":"2013","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.jphs.2025.09.007_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.drudis.2019.11.017","article-title":"ROCK-2-selective targeting and its therapeutic outcomes","volume":"25","author":"Sharma","year":"2020","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.jphs.2025.09.007_bib46","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and drug administration-approved therapies for chronic GVHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jphs.2025.09.007_bib47","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","article-title":"FDA approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy","volume":"28","author":"Przepiorka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jphs.2025.09.007_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.585633","article-title":"The physiology, pathology, and therapeutic interventions for ROCK Isoforms in diabetic kidney disease","volume":"11","author":"Matoba","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:20:35Z","timestamp":1763446835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861325000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1347861325000933"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.09.007","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rho kinase 2 promotes epithelial-mesenchymal transition and proliferation in human prostate cancer PC-3\u00a0cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}